A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent
 participants with aHUS.
Inclusion Criteria:

 -  Body weight >= 40 kg at screening.

 -  Vaccination against Neisseria meningitidis.

 -  For participants receiving other therapies (e.g., immunosuppressants, corticosteroids,
 mTORi, or calcineurin inhibitors: stable dose for 28 days.

 -  For female participants of childbearing potential: an agreement to remain abstinent or
 use contraception.

 -  Participants with a prior kidney transplant are eligible if they have a known history
 of complement-mediated aHUS prior to the kidney transplant.

 -  Evidence of TMA (for Naive Cohort only).

 -  Onset of TMA =<28 days prior to first crovalimab administration (for Naive Cohort
 only).

 -  Documented treatment with a C5 inhibitor (for Switch Cohort only).

 -  Clinical evidence of response to a C5 inhibitor (for Switch Cohort only).

 -  Known C5 polymorphism (for C5 SNP Cohort only).

 -  Poorly controlled TMA following treatment with another C5 inhibitor (for C5 SNP Cohort
 only).

 Exclusion Criteria:

 -  TMA associated with non-aHUS related renal disease.

 -  Positive direct Coombs test.

 -  Chronic dialysis and/or end stage renal disease.

 -  Identified drug exposure-related TMA.

 -  Presence or history of a condition that could trigger TMA, such as malignancy, organ
 transplant (other than kidney transplant) or autoimmune disease.

 -  History of a kidney disease, other than aHUS.

 -  History of Neisseria meningitidis infection within 6 months.

 -  Known or suspected immune deficiency (e.g., history of frequent recurrent infections).

 -  Positive HIV test.

 -  Multi-system organ dysfunction or failure.

 -  Recent IVIg treatment.

 -  Pregnant or breastfeeding or intending to become pregnant.

 -  Participation in another interventional treatment study with an investigational agent
 or use of any experimental therapy within 28 days of screening or within five half
 lives of that investigational product, whichever is greater.

 -  Recent use of tranexamic acid.

 -  Current or previous treatment with a complement inhibitor (for Naïve Cohort only).

 -  Positive for Active Hepatitis B and C infection (HBV/HCV) (for Switch Cohort and C5
 SNP Cohort participants who recently received C5 inhibitor treatment).

 -  Cryoglobulinemia at screening (for Switch Cohort and C5 SNP Cohort participants who
 recently received C5 inhibitor treatment).

 -  Documented condition leading to non-aHUS TMA: Thrombotic Thrombocytopenic Purpura
 (TTP), Shiga Toxin producing Escherichia Coli (STEC)-TMA, Pneumococcal HUS, TMA
 secondary to cobalamin C defect and TMA related to Diacylglycerol kinase ε (DGKE)
 nephropathy.